Syneos Health Signs Agreement with GoBroad Healthcare Group to Support Clinical Trials in China
November 2, 2023
MORRISVILLE, N.C. – November 2, 2023 – Syneos Health®, a leading fully integrated biopharmaceutical solutions organization, has signed an agreement with GoBroad Healthcare Group. The agreement further expands the Company’s clinical trial capabilities across a broader range of therapeutic areas in China.
GoBroad Healthcare Groupnow becomes part of the Syneos Health Catalyst and Site Network Partnerships program, including 110+ clinical sites and 60+ commercial site networks. As part of the Site Network Partnerships program, GoBroad Healthcare Group joins a select set of high-performing investigative site networks strategically aligned to the Syneos Health clinical studies. Site Network Partnerships provide enhanced patient access, improved efficiencies, specialized expertise and access to diverse patient populations across all therapeutic areas and phases.
“This agreement with GoBroad Healthcare Groupis part of our global strategy to optimize our work with sites and sponsors in this rapidly growing and changing market,” said Serena Chan, VP, Clinical Development, Syneos Health. “We remain committed to our customers, executing fit-for-purpose solutions that address their unique and complex needs.”
GoBroad Healthcare Group is committed to building a clinically driven and innovative medical technology platform with the philosophy of "patients' needs come first.” The Group’s mission and vision are rooted in pursuing excellence in diagnosis and treatment, utilizing innovative technology and creating possibilities for life.
Dr. Xiaoyu Zheng, VP GoBroad Group, CEO of GoBroad Clinical Research Center, Executive Director of Boren Hospital and Gobroad Hospital said, “GoBroad Healthcare Group has been actively engaged in strategic cooperation with various parties to participate in the rapid development of innovative drug research and development by leveraging research-oriented sites. By partnering with Syneos Health, we will further expand our global perspective and promote cutting-edge technology to fully empower and drive the different stages of new drug research and development to benefit patients.”
About Syneos Health
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.
Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.
Syneos Press/Media Contact:
Executive Director, External Communications
+1 908 763 3428